NEUCA S.A (NEU) Fair Value & Analysis
Healthcare · PL · Market cap 3.2B PLN
Fair value as of: Jun 24, 2026
From 26 valuation models · updated 5 days ago
Share price −5.6% over the past month.
Price vs Fair Value (12 months)
12‑month range 662.07 PLN – 867.12 PLN · fair‑value band 560.78 PLN – 1,074 PLN · the 709.00 PLN price screens below the 817.23 PLN fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
NEUCA S.A (NEU) currently trades at 709.00 PLN, while our model-based Fair Value estimate is 817.23 PLN — implying the stock looks roughly 15.3% undervalued today. We read business quality at 90/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Over the trailing twelve months, NEUCA S.A generated revenue of 13.8B PLN at a net margin of 1.3%. Revenue grew 5.7% year over year. It earns a return on equity of 12.4%. Net debt stands at 169M PLN. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
NEUCA S.A. engages in the wholesale distribution of pharmaceuticals in Poland. It operates through Wholesale Distribution of Medicines, Manufacture of Pharmaceuticals, Medical Operator, Clinical Trials, and Insurance Activities segments. The company offers Rx, OTC drugs, dietary supplements, medical devices, dermocosmetics, hygiene products, personal protective equipment, as well as diagnostic and dressing materials under the Swiat Zdrowia, APTEO, GENOPTIM, CERA+ Solutions, and Kic Kic brands. It also provides medical care services, including prevention, diagnostics, treatment, and complementary services; and financing services, such as insurance, subscriptions, occupational medicine, preventive and medicine programmes, FFS, NFZ, public, private, and corporate payer services. In addition, the company offers TPA services, remote consultations, in person visits, diagnostic tests, and occupational medicine services; operates a medical helpline and medical facilities; and offers medicin…
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
NEUCA S.A reported revenue of 13.6B PLN in FY2025 versus 9.9B PLN in FY2021, a compound +8.4%/yr. Reported net income was 156M PLN in FY2025, compounding +0.8%/yr from FY2021.
Open the full interactive analysis →
Similar stocks
6 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| McKesson Corporation M1CK34 | R$1,022 | R$1,243 | +22% |
| Cencora, Inc C1CO34 | R$709.32 | R$400.70 | -44% |
| Cardinal Health, Inc CAH | $216.30 | $110.75 | -49% |
| Sigma Healthcare Limited SIGGF | $2.35 | $0.7800 | -67% |
| Sitka Gold Corp SIG | A$2.76 | A$0.3300 | -88% |
| Shanghai Pharmaceuticals Holding 601607 | ¥15.96 | ¥56.73 | +255% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is NEUCA S.A (NEU) undervalued?
What is the fair value of NEU?
What is the quality score of NEU?
What is the revenue of NEUCA S.A (NEU)?
What is the net profit margin of NEU?
Does NEUCA S.A pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.